Announcement

Since news of the Pfizer-BioNTech COVID-19 vaccine first broke in November 2020, growing recognition has been given to the Canadian nanomedicine-based component underlying the vaccine’s effectiveness: the lipid nanoparticle (LNP) delivery system that originated from basic research by NMIN Scientific Director Dr. Pieter Cullis that started over 40 years ago… Read More »Recognition grows for role of LNPs and Canadian biotech in COVID-19 mRNA-based vaccines

Edmonton-based company Entos Pharmaceuticals has developed a new DNA-based vaccine for COVID-19 that is expected to enter Phase 1 clinical trials soon. NMIN researcher Dr. John Lewis, associate professor of oncology at the University of Alberta, is CEO of Entos. At the outset of the pandemic, the company repurposed its… Read More »NMIN researcher’s company develops new DNA-based COVID-19 vaccine

NMIN is pleased to announce the launch of three interactive, online intellectual property (IP) management tools. Developed by NMIN in collaboration with patent agent Wendy Lamson (Perley-Robertson, Hill & McDougall), these tools are now available on the NMIN website. These three interactive online tools were developed to help researchers and… Read More »NMIN launches online IP management / patenting tools

https://youtu.be/M-NUP8Xs9-g Above: watch the 26 April 2021 coverage of this story by GlobalNews. See also the CIHR’s timeline and video “The long road to mRNA vaccines,” featuring the contributions highlighted here. Pfizer caught the world’s attention with its promising early results for a COVID-19 vaccine candidate. What has been less… Read More »Canadian technology enables Pfizer’s COVID-19 vaccine